Revolution Medicines, Inc. $RVMD Shares Sold by Jasper Ridge Partners L.P.

Jasper Ridge Partners L.P. trimmed its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 59.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,809 shares of the company’s stock after selling 8,559 shares during the quarter. Jasper Ridge Partners L.P.’s holdings in Revolution Medicines were worth $1,088,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of RVMD. Contravisory Investment Management Inc. purchased a new stake in Revolution Medicines in the second quarter valued at approximately $32,000. ABS Investment Management LLC acquired a new position in Revolution Medicines in the 2nd quarter worth approximately $337,104,000. Johnson Financial Group Inc. purchased a new position in Revolution Medicines during the 2nd quarter worth approximately $37,000. Northwestern Mutual Wealth Management Co. purchased a new position in Revolution Medicines during the 2nd quarter worth approximately $41,000. Finally, Silvant Capital Management LLC acquired a new stake in Revolution Medicines during the 2nd quarter valued at approximately $41,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. TD Cowen raised shares of Revolution Medicines to a “strong-buy” rating in a report on Monday, August 24th. Wolfe Research reissued an “outperform” rating and set a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Needham & Company LLC upped their price target on shares of Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $248.00 price target on shares of Revolution Medicines in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $198.89.

Insider Buying and Selling at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 4,175 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $651,801.00. Following the sale, the insider directly owned 291,876 shares in the company, valued at $45,567,681.12. This trade represents a 1.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer owned 123,269 shares in the company, valued at $20,749,870.77. This trade represents a 13.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is currently owned by company insiders.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Stock Performance

RVMD opened at $207.88 on Friday. The firm has a fifty day moving average price of $193.33 and a 200 day moving average price of $148.59. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The stock has a market cap of $44.56 billion, a P/E ratio of -23.57 and a beta of 1.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the business posted ($1.31) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -8.85 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.